3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Renal Cell
23
Kidney Neoplasms
7
Carcinoma, Hepatocellular
7
Osteosarcoma
5
Sarcoma, Ewing
4
Neoplasm Metastasis
4
Sarcoma
3
Clear-cell metastatic renal cell carcinoma
3
Recurrence
2
Prostatic Neoplasms
2
Neuroendocrine Tumors
2
Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Transitional Cell
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma
2
Adrenocortical Carcinoma
2
von Hippel-Lindau Disease
1
Wilms Tumor
1
Urogenital Neoplasms
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Urachal adenocarcinoma
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Sjogren's Syndrome
1
Scleroderma, Systemic
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Refractory Differentiated Thyroid Gland Carcinoma
1
Interventions
belzutifan
3
palbociclib
1
lenvatinib
1
gallium Ga 68 dotatate
1
cabozantinib
1
Propranolol
1
Nivolumab
1
Everolimus
1
Blood Specimen Collection
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
von Hippel-Lindau Disease
×
cabozantinib
×
Clear all
NCT07405164
2026-05-29
MK-6482-043
Merck Sharp & Dohme LLC
Phase 3
Recruiting
450 enrolled